AP2359A - Sulfonamide derivatives for the treatment of diseases. - Google Patents

Sulfonamide derivatives for the treatment of diseases.

Info

Publication number
AP2359A
AP2359A AP2006003669A AP2006003669A AP2359A AP 2359 A AP2359 A AP 2359A AP 2006003669 A AP2006003669 A AP 2006003669A AP 2006003669 A AP2006003669 A AP 2006003669A AP 2359 A AP2359 A AP 2359A
Authority
AP
ARIPO
Prior art keywords
diseases
treatment
sulfonamide derivatives
sulfonamide
derivatives
Prior art date
Application number
AP2006003669A
Other languages
English (en)
Other versions
AP2006003669A0 (en
Inventor
Alan Daniel Brown
Mark Edward Bunnage
Paul Alan Glossop
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36954179&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2359(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0406387A external-priority patent/GB0406387D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of AP2006003669A0 publication Critical patent/AP2006003669A0/xx
Application granted granted Critical
Publication of AP2359A publication Critical patent/AP2359A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AP2006003669A 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases. AP2359A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04290169 2004-01-22
GB0406387A GB0406387D0 (en) 2004-03-22 2004-03-22 Sulfonamide derivatives for the treatment of diseases
US60026004P 2004-08-09 2004-08-09
PCT/IB2005/000086 WO2005080313A2 (fr) 2004-01-22 2005-01-12 Derives de sulfonamides utilises dans le traitement de maladies

Publications (2)

Publication Number Publication Date
AP2006003669A0 AP2006003669A0 (en) 2006-06-30
AP2359A true AP2359A (en) 2012-01-30

Family

ID=36954179

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2006003669A AP2359A (en) 2004-01-22 2005-01-12 Sulfonamide derivatives for the treatment of diseases.

Country Status (30)

Country Link
US (4) US7244766B2 (fr)
EP (1) EP1708991B1 (fr)
JP (1) JP4020954B2 (fr)
AP (1) AP2359A (fr)
AR (1) AR047509A1 (fr)
AT (1) ATE375977T1 (fr)
AU (1) AU2005214153B2 (fr)
BR (1) BRPI0507085A (fr)
CA (1) CA2553789C (fr)
DE (1) DE602005002930T2 (fr)
DK (1) DK1708991T3 (fr)
DO (1) DOP2005000006A (fr)
EA (1) EA011167B1 (fr)
ES (1) ES2293530T3 (fr)
GE (1) GEP20094781B (fr)
MY (1) MY143390A (fr)
NL (1) NL1028087C2 (fr)
NO (1) NO20062983L (fr)
NZ (1) NZ548318A (fr)
OA (1) OA13362A (fr)
PA (1) PA8622001A1 (fr)
PE (1) PE20051136A1 (fr)
PL (1) PL1708991T3 (fr)
PT (1) PT1708991E (fr)
RS (1) RS50561B (fr)
SI (1) SI1708991T1 (fr)
TW (1) TWI341831B (fr)
UA (1) UA84048C2 (fr)
UY (1) UY28721A1 (fr)
WO (1) WO2005080313A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50561B (sr) * 2004-01-22 2010-05-07 Pfizer Inc. Derivati sulfonamida za lečenje bolesti
GB0425054D0 (en) * 2004-03-23 2004-12-15 Pfizer Ltd Formamide derivatives for the treatment of diseases
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1695973A1 (fr) * 2005-02-24 2006-08-30 Neuro3D Sel d'Ocaperidone et composition pharmaceutique le contenant.
WO2007010356A2 (fr) * 2005-07-18 2007-01-25 Pfizer Limited Procede pour la preparation de derives de sulfonamide
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
ATE549337T1 (de) 2006-04-21 2012-03-15 Novartis Ag Purinderivate zur verwendung als adenosin-a2a- rezeptoragonisten
JP4948913B2 (ja) * 2006-06-16 2012-06-06 上野製薬株式会社 ナフタレンカルボン酸アミドの製造方法
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
SG172444A1 (en) 2008-12-30 2011-07-28 Pulmagen Therapeutics Inflammation Ltd Sulfonamide compounds for the treatment of respiratory disorders
WO2010136940A1 (fr) 2009-05-29 2010-12-02 Pfizer Limited Nouveaux agonistes du récepteur des glucocorticoïdes
WO2010150014A1 (fr) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited Glitazones 5r-5–deutérés pour le traitement de maladies respiratoires
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
WO2011098746A1 (fr) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Sels d'addition acide cristallins de l'énantiomère (5r) de la pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
WO2013021309A1 (fr) 2011-08-11 2013-02-14 Pfizer Limited Intermédiaire et procédé de préparation d'un dérivé sulfonamide
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659737A2 (fr) * 1993-12-21 1995-06-28 Bristol-Myers Squibb Company Substituts pour Catécholamines utiles comme agonistes B3
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
WO2003099764A1 (fr) * 2002-05-28 2003-12-04 Theravance, Inc. Agonistes du recepteur adrenergique $g(b)2 alcoxy aryle
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
WO2004100950A1 (fr) * 2003-05-15 2004-11-25 Pfizer Limited Derives de (2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)-propylphenyle utilises comme beta2 agonistes

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US143034A (en) * 1873-09-23 Improvement in rocking-grates
US229058A (en) * 1880-06-22 spencer
US4404224A (en) 1981-12-02 1983-09-13 American Cyanamid Company Alkanesulfonanilide derivatives and pharmaceutically acceptable acid addition salts thereof for increasing the growth rate and/or improving the lean meat to fat ratio of warm blooded animals
US4540581A (en) 1984-01-31 1985-09-10 Bristol-Myers Company Topical nonsteroidal anti-inflammatory compositions and uses
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5264067A (en) 1992-04-23 1993-11-23 Geber Garment Technology, Inc. Adjustable length carriage compatible for use with differing spreading table widths and types
SE9700135D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
JPH10218861A (ja) 1997-02-04 1998-08-18 Yamanouchi Pharmaceut Co Ltd 新規なフェネタノール誘導体又はその塩
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
BR9810456A (pt) * 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
HRP20000765A2 (en) * 2000-11-10 2002-06-30 Pliva D D Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release
US7048994B2 (en) 2001-02-23 2006-05-23 Teijin Limited Laminated polyester film and magnetic recording medium
US20030185700A1 (en) * 2002-03-26 2003-10-02 The Japan Steel Works, Ltd. Heat-resisting steel and method of manufacturing the same
RS50561B (sr) * 2004-01-22 2010-05-07 Pfizer Inc. Derivati sulfonamida za lečenje bolesti

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659737A2 (fr) * 1993-12-21 1995-06-28 Bristol-Myers Squibb Company Substituts pour Catécholamines utiles comme agonistes B3
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US20020143034A1 (en) * 1998-12-30 2002-10-03 Fujisawa Pharmaceutical Co. Ltd. Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
US20030229058A1 (en) * 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
WO2003099764A1 (fr) * 2002-05-28 2003-12-04 Theravance, Inc. Agonistes du recepteur adrenergique $g(b)2 alcoxy aryle
WO2004100950A1 (fr) * 2003-05-15 2004-11-25 Pfizer Limited Derives de (2-hydroxy-2-(4-hydroxy-3-hydoxymethylphenyl)-ethylamino)-propylphenyle utilises comme beta2 agonistes

Also Published As

Publication number Publication date
RS50561B (sr) 2010-05-07
US7767715B2 (en) 2010-08-03
SI1708991T1 (sl) 2008-02-29
OA13362A (en) 2007-04-13
UA84048C2 (ru) 2008-09-10
WO2005080313A2 (fr) 2005-09-01
EP1708991B1 (fr) 2007-10-17
US20100273758A1 (en) 2010-10-28
NO20062983L (no) 2006-07-24
PT1708991E (pt) 2007-12-14
NL1028087C2 (nl) 2006-05-09
PL1708991T3 (pl) 2008-02-29
GEP20094781B (en) 2009-09-25
TWI341831B (en) 2011-05-11
US20050182091A1 (en) 2005-08-18
WO2005080313A3 (fr) 2005-12-01
MY143390A (en) 2011-05-13
EA011167B1 (ru) 2009-02-27
AU2005214153B2 (en) 2008-09-18
US8013019B2 (en) 2011-09-06
DOP2005000006A (es) 2005-07-31
ATE375977T1 (de) 2007-11-15
EP1708991A2 (fr) 2006-10-11
ES2293530T3 (es) 2008-03-16
US20080267970A1 (en) 2008-10-30
AR047509A1 (es) 2006-01-25
AP2006003669A0 (en) 2006-06-30
NZ548318A (en) 2009-03-31
US7244766B2 (en) 2007-07-17
JP4020954B2 (ja) 2007-12-12
DE602005002930D1 (de) 2007-11-29
US20090197912A1 (en) 2009-08-06
US7528170B2 (en) 2009-05-05
EA200601223A1 (ru) 2006-12-29
DE602005002930T2 (de) 2008-07-24
PE20051136A1 (es) 2006-02-18
BRPI0507085A (pt) 2007-06-19
UY28721A1 (es) 2005-08-31
CA2553789C (fr) 2011-07-19
PA8622001A1 (es) 2005-08-30
WO2005080313A9 (fr) 2006-08-31
DK1708991T3 (da) 2008-01-14
JP2007518789A (ja) 2007-07-12
AU2005214153A1 (en) 2005-09-01
NL1028087A1 (nl) 2005-07-25
CA2553789A1 (fr) 2005-09-01
TW200530165A (en) 2005-09-16

Similar Documents

Publication Publication Date Title
AP2378A (en) Sulfonamide derivatives for the treatment of diseases.
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
LTC1830843I2 (lt) Indolidono dariniai, skirti fibrozinių ligų gydymui arba prevencijai
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
IL184934A0 (en) 4-oxoquinazoline-3-yl-benzamide derivatives for the treatment of cytokine diseases
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
GB0523961D0 (en) The treatment of ophthalmic diseases
EP1768656A4 (fr) Traitement de maladies oculaires
GB0400802D0 (en) Compounds for the treatment of disease
GB0523964D0 (en) The treatment of ophthalmic diseases
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
ZA200606780B (en) Compounds for the treatment of diseases
IL176564A0 (en) Sulfonamide derivatives for the treatment of diseases
GB0406387D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0406388D0 (en) Sulfonamide derivatives for the treatment of diseases
GB0425054D0 (en) Formamide derivatives for the treatment of diseases
GB0425073D0 (en) Compounds for the treatment of diseases
IL177531A0 (en) Compounds for the treatment of diseases
GB0420867D0 (en) Compounds for the treatment of diseases
GB0408297D0 (en) Indole derivatives for the treatment of diseases
GB0415352D0 (en) Compounds for the treatment of disease
GB0523962D0 (en) The treatment of ophthalmic diseases
GB0523965D0 (en) The treatment of ophthalmic diseases
GB0425064D0 (en) Compounds useful for the treatment of diseases